Litcius/Paper detail

Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study

Dai Maruyama, Eric D. Jacobsen, Pierluigi Porcu, Pamela B. Allen, Kenji Ishitsuka, Shigeru Kusumoto, Tomoko Narita, Kensei Tobinai, Francine Foss, Kunihiro Tsukasaki, Tatyana Feldman, Yoshitaka Imaizumi, Koji Izutsu, Satoko Morishima, Nobuhiko Yamauchi, Junichiro Yuda, Jonathan E. Brammer, Toyotaka Kawamata, Jia Ruan, Kisato Nosaka, Atae Utsunomiya, Jie Wang, Jasmine Zain, Yasuyuki Kakurai, Hideyuki Yamauchi, Yoshiyuki Hizukuri, Noha Biserna, Masaya Tachibana, Ai Inoue, Sarah McCue Horwitz

2024The Lancet Oncology23 citationsDOI

Topics & Concepts

Refractory (planetary science)Open labelMedicineHodgkin lymphomaLymphomaOncologyPhases of clinical researchInternal medicineChemotherapyClinical trialMaterials scienceComposite materialLymphoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchCNS Lymphoma Diagnosis and Treatment
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study | Litcius